<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843660</url>
  </required_header>
  <id_info>
    <org_study_id>CR016117</org_study_id>
    <secondary_id>TRAMAPPAI4035</secondary_id>
    <secondary_id>TRAMAP-CHN-MA-02</secondary_id>
    <nct_id>NCT01843660</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Tramadol Hydrochloride-Paracetamol in Treatment of Moderate to Severe Acute Neck-Shoulder Pain and Low Back Pain</brief_title>
  <official_title>The Clinical Efficacy and Safety Study of Tramadol Hydrochloride - Paracetamol Tablets in the Treatment of Moderate to Severe Acute Neck-shoulder Pain and Low Back Pain in Orthopaedics Outpatient or Emergency Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xian-Janssen Pharmaceutical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xian-Janssen Pharmaceutical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of tramadol
      hydrochloride-paracetamol tablets in treatment of moderate (medium level of seriousness) to
      severe (very serious) acute neck, shoulder and low back pain in orthopedics (pertaining to
      the bones) outpatient or emergency setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (all people know the identity of the intervention), non-randomized,
      multi-center (when more than one hospital or medical school team work on a medical research
      study) and prospective (study following participants forward in time) study of tramadol
      hydrochloride-paracetamol tablets. Participants will receive 1 to 2 tablets of tramadol
      hydrochloride-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram
      [mg] and paracetamol 325mg). Participants may be given the additional dose according to the
      clinical requirement. The total treatment duration will be 6 hours. The total study duration
      will be 4 months. Efficacy will be evaluated primarily by pain intensity and pain relief.
      Participants will evaluate the pain severity and pain relief at 0.5, 1, 2, 3, 4 and 6 hours
      respectively after the first dose; and the drug efficacy and overall satisfaction level at
      the end of 6 hours after the first dose. Participants' safety will be monitored throughout
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 0.5</measure>
    <time_frame>Hour 0.5</time_frame>
    <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 1</measure>
    <time_frame>Hour 1</time_frame>
    <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 2</measure>
    <time_frame>Hour 2</time_frame>
    <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 3</measure>
    <time_frame>Hour 3</time_frame>
    <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 4</measure>
    <time_frame>Hour 4</time_frame>
    <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 6</measure>
    <time_frame>Hour 6</time_frame>
    <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pain Relief Score at Hour 0.5</measure>
    <time_frame>Hour 0.5</time_frame>
    <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pain Relief Score at Hour 1</measure>
    <time_frame>Hour 1</time_frame>
    <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pain Relief Score at Hour 2</measure>
    <time_frame>Hour 2</time_frame>
    <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pain Relief Score at Hour 3</measure>
    <time_frame>Hour 3</time_frame>
    <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pain Relief Score at Hour 4</measure>
    <time_frame>Hour 4</time_frame>
    <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Pain Relief Score at Hour 6</measure>
    <time_frame>Hour 6</time_frame>
    <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Required Additional Dosage Administration</measure>
    <time_frame>Baseline up to Hour 2</time_frame>
    <description>Number of participants who additionally required a second tablet within 2 hours after the first administration of the investigational drug was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Analgesic Satisfaction Score</measure>
    <time_frame>Hour 6</time_frame>
    <description>Participants evaluated their satisfaction with the analgesic effect of the study drug using a 4-point scale (4=very good, 3=good, 2=average, 1=poor). Number of participants in each category was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Analgesic Satisfaction Score</measure>
    <time_frame>Hour 6</time_frame>
    <description>Participants and physicians separately evaluated their satisfaction with the analgesic effect of the study drug using a 5-point scale (1=very unsatisfied, 2 =unsatisfied, 3=average, 4= satisfied and 5=very satisfied). Number of participants in each category was reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1059</enrollment>
  <condition>Low Back Pain</condition>
  <condition>Shoulder Pain</condition>
  <condition>Neck Pain</condition>
  <arm_group>
    <arm_group_label>Tramadol Hydrochloride (HCl)-Paracetamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol HCl-Paracetamol</intervention_name>
    <description>Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.</description>
    <arm_group_label>Tramadol Hydrochloride (HCl)-Paracetamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermittent or persistent pain for less than 3 months, required analgesic therapy,
             orthopedic surgery and emergency call participants suffering with severe neck,
             shoulder, low back pain or chronic neck, shoulder, lower back pain, acute (a quick and
             severe form of illness in its early stage) exacerbation pain

          -  Pain intensity to be assessed using Numerical Rating Scale (NRS), NRS score more than
             or equal to 4 (from 0 to 10, 0 = no pain, 10 = extreme pain)

          -  During normal pain and stable feeling, can study pain assessment methods and can fill
             in pain control diary

          -  Be willing to participate in the study and must give written informed consent

        Exclusion Criteria:

          -  Have used strong opium kind of medication 7 days prior to the enrolment

          -  Have severe mental disease or using antipsychotic (agent that control agitated
             psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and
             exert a quieting effect) medication for medical treatment

          -  Drug abuse/dependence, or chronic alcohol abuse/depend on history

          -  Pregnant or lactating women

          -  Unable to tolerate tramadol or any failed treatment in past by using tramadol

          -  Comparatively more severe pain in other parts of the body than that of the pain
             mentioned in the research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xian-Janssen Pharmaceutical Ltd., China Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Xian-Janssen Pharmaceutical Ltd.</affiliation>
  </overall_official>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2013</study_first_posted>
  <results_first_submitted>June 18, 2013</results_first_submitted>
  <results_first_submitted_qc>June 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2013</results_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low back pain</keyword>
  <keyword>Shoulder pain</keyword>
  <keyword>Neck pain</keyword>
  <keyword>Tramadol hydrochloride</keyword>
  <keyword>Paracetamol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Neck Pain</mesh_term>
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
          <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1059"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1029"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Out of a total of 1059 participants, baseline characteristic (age and gender) was available for only 1035 participants who were included in the full analysis set.</population>
      <group_list>
        <group group_id="B1">
          <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
          <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1035"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.43" spread="12.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 0.5</title>
        <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
        <time_frame>Hour 0.5</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 0.5</title>
          <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 1</title>
        <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
        <time_frame>Hour 1</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 1</title>
          <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 2</title>
        <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
        <time_frame>Hour 2</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 2</title>
          <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.52" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 3</title>
        <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
        <time_frame>Hour 3</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 3</title>
          <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 4</title>
        <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
        <time_frame>Hour 4</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 4</title>
          <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 6</title>
        <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
        <time_frame>Hour 6</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Score Based on Numeric Rating Scale (NRS) at Hour 6</title>
          <description>Pain intensity was measured using NRS (0=painless and 10=most severe pain). Score of 1-3 means mild pain; 4-6 means moderate pain and 7-10 means severe pain.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pain Relief Score at Hour 0.5</title>
        <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
        <time_frame>Hour 0.5</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Relief Score at Hour 0.5</title>
          <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exacerbated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pain Relief Score at Hour 1</title>
        <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
        <time_frame>Hour 1</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Relief Score at Hour 1</title>
          <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exacerbated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pain Relief Score at Hour 2</title>
        <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
        <time_frame>Hour 2</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Relief Score at Hour 2</title>
          <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exacerbated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pain Relief Score at Hour 3</title>
        <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
        <time_frame>Hour 3</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Relief Score at Hour 3</title>
          <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exacerbated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pain Relief Score at Hour 4</title>
        <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
        <time_frame>Hour 4</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Relief Score at Hour 4</title>
          <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exacerbated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Pain Relief Score at Hour 6</title>
        <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
        <time_frame>Hour 6</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pain Relief Score at Hour 6</title>
          <description>Pain relief was measured using 6-point Likert Scale (4=complete, 3=significant/comparatively large, 2=moderate, 1=mild/slight, 0=none, -1=exacerbated/heavier).</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exacerbated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Required Additional Dosage Administration</title>
        <description>Number of participants who additionally required a second tablet within 2 hours after the first administration of the investigational drug was reported.</description>
        <time_frame>Baseline up to Hour 2</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Required Additional Dosage Administration</title>
          <description>Number of participants who additionally required a second tablet within 2 hours after the first administration of the investigational drug was reported.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Analgesic Satisfaction Score</title>
        <description>Participants evaluated their satisfaction with the analgesic effect of the study drug using a 4-point scale (4=very good, 3=good, 2=average, 1=poor). Number of participants in each category was reported.</description>
        <time_frame>Hour 6</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Analgesic Satisfaction Score</title>
          <description>Participants evaluated their satisfaction with the analgesic effect of the study drug using a 4-point scale (4=very good, 3=good, 2=average, 1=poor). Number of participants in each category was reported.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Analgesic Satisfaction Score</title>
        <description>Participants and physicians separately evaluated their satisfaction with the analgesic effect of the study drug using a 5-point scale (1=very unsatisfied, 2 =unsatisfied, 3=average, 4= satisfied and 5=very satisfied). Number of participants in each category was reported.</description>
        <time_frame>Hour 6</time_frame>
        <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
            <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Analgesic Satisfaction Score</title>
          <description>Participants and physicians separately evaluated their satisfaction with the analgesic effect of the study drug using a 5-point scale (1=very unsatisfied, 2 =unsatisfied, 3=average, 4= satisfied and 5=very satisfied). Number of participants in each category was reported.</description>
          <population>Per protocol population included all participants who completed the clinical trial according to the trial protocol.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1029"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants' evaluation: Very unsatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants' evaluation: Unsatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants' evaluation: Average</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants' evaluation: Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants' evaluation: Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physicians' evaluation: Very unsatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physicians' evaluation: Unsatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physicians' evaluation: Average</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physicians' evaluation: Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physicians' evaluation: Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tramadol Hydrochloride (HCl)-Paracetamol</title>
          <description>Participants received 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325 mg) for up to a total duration of 6 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1059"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>No coding applied</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1059"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1059"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1059"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1059"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1059"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1059"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1059"/>
              </event>
              <event>
                <sub_title>Skin itch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1059"/>
              </event>
              <event>
                <sub_title>Others</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1059"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Disclosure restriction on the PI is that the PI should submit manuscript to the Sponsor for review no less than 60 days prior to public release. Only with written approval of the Sponsor, the results communications could be public released.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Results are reported for 'number of participants who required additional dosage administration' instead of 'time to achieve analgesic effect' due to change in planned analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Physician</name_or_title>
      <organization>Janssen China, Beijing</organization>
      <phone>+86-10-58218709</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

